Literature DB >> 2556505

Hypothalamic expression of a novel gene product, VGF: immunocytochemical analysis.

A N van den Pol1, C Decavel, A Levi, B Paterson.   

Abstract

VGF is the designation for a new 712 amino acid protein, regulated by nerve growth factor (NGF) in PC12 cells, that has not been previously described in the CNS. Northern blot analysis with a nick-translated VGF cDNA probe revealed a single band of mRNA in the brain with a molecular weight identical to that found in PC12 cells. The current paper presents a series of immunocytochemical studies of VGF expression with a focus on the hypothalamus. Two different antisera were raised against nonoverlapping amino acid sequences of a bacterial-expressed protein from the VGF gene cloned from PC12 cells. VGF immunoreactivity is strongly expressed in the rat suprachiasmatic nucleus (SCN), particularly in the dorsomedial part of the nucleus. The administration of colchicine to block axonal transport facilitates detection of the VGF immunoreactivity also in the ventrolateral suprachiasmatic nucleus. This protein appears to be the first one of limited neuronal distribution which is found in both dorsomedial SCN and ventrolateral SCN. Immunostaining of serial 1 micron SCN sections reveals co-localization of VGF in cells which also contain vasopressin or vasoactive intestinal polypeptide. Weaker immunoreactivity is also found in the magnocellular paraventricular and supraoptic nuclei, where the VGF immunoreactivity co-localizes with oxytocin or vasopressin. Mutant Brattleboro rats which do not express vasopressin showed strong VGF immunoreactivity both in the dorsomedial SCN and in cells of the magnocellular neuronal systems, including cells which normally express vasopressin. When axonal transport of the protein is blocked by colchicine, VGF-immunoreactive cells in the hypothalamic arcuate, parvocellular paraventricular, and tuberomammillary nuclei can also be detected, in addition to weakly immunoreactive scattered cells in the hippocampus, amygdala, thalamus, and cortex. VGF immunoreactivity is strong in the axonal projections of SCN and weak in the axons of the paraventricular and supraoptic nuclei. With ultrastructural studies, VGF immunoreactivity is found in presynaptic boutons in the SCN and in axons in the neurohypophysis. Weak axonal staining is present in some regions of the hypothalamus and in the external and internal zones of the median eminence. Immunoreactivity is absent from the intermediate lobe of the hypophysis. In neonatal rats strong VGF immunoreactivity is found throughout the SCN at postnatal day 4 but not in the adjacent hypothalamus. VGF immunoreactivity is also seen in other areas of the brain in neonatal rats, including the lateral geniculate nucleus; while the staining in the dorsal lateral geniculate disappears in the adult, that in the intergeniculate leaflet, a visual center which projects to the SCN, remains.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556505      PMCID: PMC6569627     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  25 in total

1.  Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis.

Authors:  Stefan Busse; Hans-Gert Bernstein; Mandy Busse; Hendrik Bielau; Ralf Brisch; Christian Mawrin; Susan Müller; Zoltán Sarnyai; Tomasz Gos; Bernhard Bogerts; Johann Steiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-14       Impact factor: 5.270

2.  Structure of the gene encoding VGF, a nervous system-specific mRNA that is rapidly and selectively induced by nerve growth factor in PC12 cells.

Authors:  S R Salton; D J Fischberg; K W Dong
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

3.  Regulatory elements in the promoter region of vgf, a nerve growth factor-inducible gene.

Authors:  R Possenti; G Di Rocco; S Nasi; A Levi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

4.  Molecular heterogeneity of RET loss of function in Hirschsprung's disease.

Authors:  F Carlomagno; G De Vita; M T Berlingieri; V de Franciscis; R M Melillo; V Colantuoni; M H Kraus; P P Di Fiore; A Fusco; M Santoro
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

5.  Endogenous peptide discovery of the rat circadian clock: a focused study of the suprachiasmatic nucleus by ultrahigh performance tandem mass spectrometry.

Authors:  Ji Eun Lee; Norman Atkins; Nathan G Hatcher; Leonid Zamdborg; Martha U Gillette; Jonathan V Sweedler; Neil L Kelleher
Journal:  Mol Cell Proteomics       Date:  2009-11-10       Impact factor: 5.911

6.  Regional differences in neurotrophin availability regulate selective expression of VGF in the developing limbic cortex.

Authors:  K L Eagleson; L D Fairfull; S R Salton; P Levitt
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

Review 7.  The adrenal chromaffin granule: a model for large dense core vesicles of endocrine and nervous tissue.

Authors:  H Winkler
Journal:  J Anat       Date:  1993-10       Impact factor: 2.610

8.  Quantitative peptidomics for discovery of circadian-related peptides from the rat suprachiasmatic nucleus.

Authors:  Ji Eun Lee; Leonid Zamdborg; Bruce R Southey; Norman Atkins; Jennifer W Mitchell; Mingxi Li; Martha U Gillette; Neil L Kelleher; Jonathan V Sweedler
Journal:  J Proteome Res       Date:  2013-01-11       Impact factor: 4.466

Review 9.  Neuropeptides in depression: role of VGF.

Authors:  Smita Thakker-Varia; Janet Alder
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

10.  Role of Hypothalamic VGF in Energy Balance and Metabolic Adaption to Environmental Enrichment in Mice.

Authors:  Grant D Foglesong; Wei Huang; Xianglan Liu; Andrew M Slater; Jason Siu; Vedat Yildiz; Stephen R J Salton; Lei Cao
Journal:  Endocrinology       Date:  2016-01-05       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.